Intelligence / Healthtech / New Clinical Trials / CAMP4 Therapeutics Corporation
Clinicaltrial registered13 Nov 2026
CAMP4 Therapeutics Corporation
13 Nov 2026: Trial registered · Study of CMP-002 in Participants With SYNGAP1-Related Disorder. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 13 Nov 2026
- Title
- Study of CMP-002 in Participants With SYNGAP1-Related Disorder
- Conditions
- Nervous System Disease
- Phase
- Phase 1, Phase 2
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- Argentina
- Country
- Argentina
- Reference
- NCT07935135
- Location
- Argentina
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at CAMP4 Therapeutics Corporation
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from Argentina
New Clinical Trials
17 NovAstraZenecatrial registered · A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLCClinical12 NovNovo Nordisk A/Strial registered · A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothClinical12 NovNovo Nordisk A/Strial registered · AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothClinical5 NovNovo Nordisk A/Strial registered · A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and ObesityClinical4 NovBoehringer Ingelheimtrial registered · A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)Clinical28 OctEli Lilly and Companytrial registered · A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular RiskClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.